| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
VREX
Varex Imaging
|
May 28, 2026 | BUY |
Strong Buy
+97.4% avg upside
9 analysts
|
$18.00
76.56% Upside
|
· |
|
OBIO
Orchestra BioMed Holdings
|
May 18, 2026 | BUY |
Strong Buy
+241.9% avg upside
9 analysts
|
$10.00
158.41% Upside
|
· |
|
OPRX
OptimizeRx
|
May 13, 2026 | BUY |
Strong Buy
+154.2% avg upside
9 analysts
|
$10.00
96.86% Upside
|
+0.6% |
|
ELMD
Electromed
|
May 13, 2026 | BUY |
Strong Buy
-13.0% avg upside
6 analysts
|
$40.00
7.61% Upside
|
· |
|
TCMD
Tactile Systems Technology
|
May 07, 2026 | BUY |
Strong Buy
+58.8% avg upside
8 analysts
|
$36.00
39.44% Upside
|
+1.1% |
|
BEAT
HeartBeam
|
Mar 31, 2026 | BUY |
Buy
+487.7% avg upside
13 analysts
|
$4.00
458.38% Upside
|
-35.5% |
|
CLPT
ClearPoint Neuro
|
Mar 18, 2026 | BUY |
Strong Buy
+8.3% avg upside
7 analysts
|
$20.00
18.99% Upside
|
+21.1% |
|
XGN
Exagen
|
Mar 11, 2026 | BUY |
Strong Buy
+172.8% avg upside
10 analysts
|
$8.00
88.19% Upside
|
+17.0% |
|
SPOK
Spok Holdings
|
Feb 26, 2026 | HOLD |
Strong Buy
+66.5% avg upside
3 analysts
|
$14.00
35.77% Upside
|
-4.8% |
|
ANIK
Anika Therapeutics
|
Feb 26, 2026 | BUY |
Strong Buy
+38.2% avg upside
4 analysts
|
$18.00
26.48% Upside
|
+17.4% |
|
MBOT
Microbot Medical
|
Feb 10, 2026 | BUY |
Strong Buy
+258.1% avg upside
7 analysts
|
$5.00
165.98% Upside
|
-16.6% |
|
INGN
Inogen
|
Jan 21, 2026 | BUY |
Buy
+287.2% avg upside
7 analysts
|
$14.00
119.72% Upside
|
+0.5% |
|
INFU
InfuSystem Holdings
|
Nov 05, 2025 | BUY |
Strong Buy
+64.6% avg upside
7 analysts
|
$12.00
37.18% Upside
|
-8.6% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.